TIGIT therapies have seen promising clinical validation, spearheading the next wave of Immune Checkpoint Inhibitors. As such there has been an explosion of interest and high-scale investment into this exciting space.
Ensure your TIGIT program reaches full clinical potential through hearing from experts about optimizing the mechanism of action, refining Fc receptor co-engagement, devising effective drug design, rationalizing checkpoint combinations and utilizing biomarkers to harness the therapeutic potential of the TIGIT and DNAM-1/CD226 axes.
Join leaders in TIGIT development from GSK, Gilead Sciences, Arcus, iTeos, Compugen, BeiGene, Seattle Genetics, Mereo BioPharma, Harvard, Stanford and more!
This event will allow you to address the key challenges associated with TIGIT therapy development and propel TIGIT to clinical use. Download the event guide to see how you can get involved.